Contact Us
Drug Search Results
More Filters [+]

MT-303

Alternative Names: MT-303, MT 303, MT303
Latest Update: 2024-07-31
Latest Update Note: News Article

Product Description

GPC3-FcA LNP. (Sourced from: https://myeloidtx.com/our-pipeline/)

Mechanisms of Action: GPC3 Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Myeloid Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MT-303

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
MTX-GPC3-303

P1

Recruiting

Hepatocellular Carcinoma

2025-07-31

Recent News Events

Date

Type

Title

07/31/2024

News Article

 Myeloid Therapeutics Initiates Patient Dosing with MT-303, a Novel GPC3 Targeting RNA CAR, in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions